Thromboelastometric Profiles of Horses Affected by Exercise-Induced Pulmonary Hemorrhages by Giordano, Alessia et al.
SAGE-Hindawi Access to Research
Veterinary Medicine International
Volume 2010, Article ID 945789, 6 pages
doi:10.4061/2010/945789
Research Article
ThromboelastometricProﬁlesofHorsesAffectedby
Exercise-Induced Pulmonary Hemorrhages
Alessia Giordano, CeciliaMeazza, Marco Salvadori, andSaverioPaltrinieri
Unit of General Pathology and Parasitology, Department of Veterinary Pathology, Hygiene and Public Health, University of Milan,
Via Celoria 10, 20133 Milano, Italy
Correspondence should be addressed to Saverio Paltrinieri, saverio.paltrinieri@unimi.it
Received 13 July 2010; Revised 31 August 2010; Accepted 18 September 2010
Academic Editor: Mary M. Christopher
Copyright © 2010 Alessia Giordano et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Exercise-induced pulmonary hemorrhage (EIPH) commonly occurs in race horses. Thromboelastometry (TEM) investigates the
whole hemostatic process by evaluating the viscoelastic properties of the blood clot from its formation to ﬁbrinolysis. The aim of
this study was to assess whether horses with EIPH have abnormal thromboelastometric proﬁles. Intrinsic and extrinsic pathways,
ﬁbrinogen activity and ﬁbrinolysis were investigated by TEM before and after the race in negative controls and in horses on which
EIPH was conﬁrmed by bronchoscopy. Compared with controls, horses with EIPH had an increased coagulability in both pre- and
postrace samplings, especially for the intrinsic pathway and for the ﬁbinrolytic activity. These results suggest that coagulation is
preactivated in horses prone to develop EIPH, possibly due to recent or recurrent hemorrhage.
1.Introduction
Exercise-induced pulmonary haemorrhage (EIPH), with or
without evident epistaxis, is frequently observed in race
horses and is associated with poor performances [1]. The
etiopathogenesis of EIPH is not completely understood.
Diﬀerent pathogenic hypotheses have been proposed for
EIPH. Speciﬁcally, the possible mechanisms that contribute
to determine EIPH in horses include stress failure of
pulmonary capillaries, upper airways obstructions, small
airways diseases, blood ﬂow redistribution after exercise,
altered blood viscosity, and trauma following locomotory
impact [1–3]. The possible presence of a coagulopathy,
which, however, has not been identiﬁed using coagulation
times, has also been postulated [4].
EIPH is usually diagnosed by clinical examination and
by instrumental investigations such as bronchoscopy and/or
bronchoalveolar lavage. Both these approaches could be
disadvantageous: instrumental procedures are moderately
invasive, and the traditional clinical approach, allows to
diagnose EIPH only when horses already show evident
symptoms (epistaxis, poor performances). The availability
of a less invasive technique and/or of a diagnostic test
able to early identify this disturbance could be useful to
better manage horses with suspected EIPH and/or to prevent
possible worsening of the clinical condition.
Thromboelastometry(TEM)investigatesthecoagulation
process by evaluating the viscoelastic properties of the blood
clot from its formation to ﬁbrinolysis [5]. It is widely
employed in human medicine, and recently it has been
validated in many species including equine [6–9].
TEM could thus be a useful and noninvasive tool to
obtain early information about the haemostatic proﬁle in
horses aﬀected by EIPH.
The hypothesis of this study is that TEM, which provides
a more complete overview of the coagulation process (TEM
results depend on the interaction between cellular and solu-
ble factors involved in hemostasis) compared with coagula-
tion times (actually based only on the concentration/activity
of coagulation factors), can better identify the coagulopathy
potentially involved in the pathogenesis of EIPH. The aim
of this study is thus to investigate the possible presence of
coagulation abnormalities in horses aﬀected by EIPH using
TEM.2 Veterinary Medicine International
2.MaterialsandMethods
2.1. Animals, Samplings, and Routine Laboratory Tests. All
thehorsesinthepresentstudywerefromprivateowners,and
bothbloodwithdrawalsandbronchoscopieswereperformed
under informed consent and without causing distress to the
animals. The inclusion criteria were the absence of previ-
ous history of EIPH and/or poor performance for horses
belonging to the control group and, conversely, the presence
of a previous diagnosis of EIPH or of episodes of poor
performance for horses belonging to the EIPH group. The
only exclusion criterion, for both groups, was the presence
of hematological or biochemical abnormalities potentially
inﬂuencing the coagulation process (e.g., thrombocytopenia
or thrombocytosis, anemia, biochemical changes suggestive
of renal failure or of liver damage or insuﬃciency), as
assessed with the panel of tests described below.
Horses were sampled both before and after a standard-
ized race of 1.600 meters. In all the horses, including those
that never had EIPH episodes before this study (control
group, see below), one hour after racing, a bronchoscopy
using a side-viewing instrument (Side-viewing broncho-
scope GF-10, Olympus, Milan, Italy) was done to verify the
possible presence of hemorrhages in the respiratory tract.
Blood samples were collected from the jugular vein,
paying attention to avoid unnecessary manipulation of the
samplingsite,whichcouldresultinactivationofcoagulation.
Blood samples were then collected into nonsiliconized vacu-
tainer tubes (Venoject-Serum—code VT-050SU, Terumo
Italia Srl, Rome, Italy), to obtain serum for a basic bio-
chemical panel (ALT, ALP, GGT, total protein, albumin,
urea, and creatinine) run on an automatic biochemistry
analyzer (Cobas Mira, Roche Diagnostic, Basel, Switzerland)
using reagents provided by Real Time Diagnostic Systems
(Real Time Diagnostic Systems, Viterbo, Italy) and into glass
vacutainer tubes speciﬁc for coagulation tests (Venoject-
Coagulation—code VT-050SBCS, Terumo Italia Srl, Rome,
Italy), each containing 0.5ml buﬀered sodium citrate (3.8%,
corresponding to 0.129mol/L), which were used to perform
routine hematology and thromboelastometry, as described
below. The use of sodium citrate, instead of EDTA, is
recommended by the manufacturer of the thromboelas-
tometer, since the chelation of calcium induced by this
anticoagulant is reversible: this allows the reactivation of
coagulation after addition of the calcium chloride included
in TEM reagents. The tubes were ﬁlled to their maximum
capacity (4.5ml of blood) and transported to the lab within
2 hours at environmental temperature, as recommended to
avoid artifactual alteration of thromboelastometric results
[8]. Routine hematology was also performed on citrated
blood to avoid excessive sampling of blood and because
this anticoagulant should be preferred to EDTA for platelet
counting in horses [10]. The complete cell blood count was
performed using an impedance counter (Hemat 8, SEAC,
Calenzano (FI), Italy) already validated for equine blood
[11]. Results generated by the instrument were corrected by
the dilution factor (1:9v/v) induced by the anticoagulant.
On blood smears stained with May Gr¨ unwald-Giemsa
(Merck, Darmstadt, Germany), the diﬀerential leukocyte
count was microscopically determined on 100 cells, as well
as the platelet estimate, by counting the mean number of
platelets in 10 oil immersion ﬁelds (magniﬁcation: 1000x).
The platelet estimate was considered adequate when at least
8 platelets per ﬁeld were observed.
Based on history and on the results of routine biochem-
istry,hematology,andbronchoscopy,horsesweregroupedas
follows.
(i) Negativecontrols(NC):elevenhorses(standardbreds
a g e d2t o5y e a r s ;7f e m a l e sa n d4m a l e s ) ,w i t hn o
history of poor performances and/or of EIPH, which
did not show any clinical sign or poor performance
during racing. When sampled, these horses did not
had clinical or laboratory abnormalities, or broncho-
scopic evidence of post-race EIPH.
(ii) EIPH (E): thirteen horses (standardbred horses aged
2 to 5 years; 7 females and 6 males) aﬀected by EIPH.
These horses suﬀered previous episodes of EIPH
and, in spite of the lack of clinical and laboratory
abnormalities, post-race bronchoscopy revealed the
presence of EIPH of grade-1 severity [12].
2.2. Thromboelastometric Analyses. Thrombeloastometric
analyses were performed using the thromboelastometer
Rotem Gamma (TEM international GmbH, Munich, Ger-
many) and reagents provided by the manufacturer of the
instrument and previously validated in horses [8]. The
following thromboelastometric tests were done: intrinsic
pathway (Startem + Intem); extrinsic pathway: (Startem +
Extem) ﬁbrinogen activity (Extem + Fibtem); ﬁbrinolysis
(Extem + Aptem). The last two tests were performed on
11 out of the 13 samples from horses with EIPH due
to technical reasons that hampered a correct evaluation
of thromboelastograms regarding ﬁbrinogen activity and
ﬁbrinolysis in two samples.
For each test, the following parameters of the thromboe-
lastogram were evaluated.
(i) Coagulation time (CT) (Figure 1): time (in seconds)
between the start of the test and the formation of the
ﬁrst measurable clot (amplitude of the thromboelas-
togram: 2mm); the CT basically reﬂects the activity
of plasma coagulation factors.
(ii) Clot formation time (CFT) (Figure 1): time (in
seconds) necessary to increase the amplitude of the
thromboelastometric tracing from 2 to 20mm; the
CFT depends on the initial activation of platelets and
ﬁbrinogen.
(iii) Alpha-angle (α) (Figure 1): slope (expressed in
degrees) of the tangent to the elasticity curve;
increases or decreases of this angle indicate a trend to
hypercoagulation or hypocoagulation, respectively.
(iv) Maximum clot ﬁrmness (MCF) (Figure 1): maximum
strength of the clot (maximum amplitude, in mm, of
the thromboelastogram). The MCF depends on both
platelet and ﬁbrinogen activation in the presence of
factor XIII (which stabilizes the clot).Veterinary Medicine International 3
Table 1: Mean values ± standard deviation (median values) recorded before the race.
Controls EIPH
Prerace Postrace Prerace Postrace
RBC ×106/μl8 .7 ±0.6(8.7) 9.6 ±0.8(9.6)
† 8.0 ±0.5(7.8)
∗ 8.9 ±1.1(8.8)
†
Hct (%) 32.9 ±6.2(34.9) 38.6 ±2.6(38.9)
† 32.8 ±1.4(32.2) 37.1 ±4.4(36.3)
†
WBC ×103/μl8 .5 ±1.7(8.4) 8.9 ±2.2(8.9) 8.2 ±1.8(7.9) 8.2 ±1.6(7.8)
Platelets ×103/μl 143.8 ±36.5(135.0) 145.9 ±29.5(150.0) 144.3 ±49.3(134.0) 188.1 ±39.4(181.0)
∗
∗P<. 05versus results of controls in the same type of sampling (e.g., pre-race or post-race); †P<. 05 versus pre-race results of the same group (e.g., controls
or EIPH).
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Figure 1: Schematic representation of the thromboelastometric
proﬁle. CT: coagulation time (CT); CFT: clot formation time; α:
alpha-angle; MCF: maximum clot ﬁrmness.
(v) Maximum velocity (Vmax): maximum rate of clot
formation, expressed in mm/min. It is measured on
the ﬁrst derivative generated by the instrument [13]
and corresponds to the time required to reach the
maximum peak of thrombin generation.
(vi) Area under the curve (AUC): the area under the veloc-
ity curve measured on the ﬁrst derivative, expressed
in mm2. The AUC equals the endpoint minus the
starting point of the elasticity curve.
Theoretically, conclusive information about ﬁbrinolysis
can be achieved only after 60 minutes, when lysis is complete
and an additional parameter (maximum lysis or ML) is
provided by the instrument. From a practical point of view,
however, when ﬁbrinolysis is activated, the MCF begins
to decrease earlier and at 30mins the instrument allows
the operator to detect an increased rate of lysis (LY30). In
this study increases of LY30 were never recorded (data not
shown) and thromboelastometric runs were thus stopped
30mins after the end of the CFT.
2.3. Statistical Analysis. Mean values and standard deviation
were calculated for each group before and after the race. All
thestatistical analyseswereperformedin an Excel (Microsoft
Corp, Redmond, WA, USA) spreadsheet with the Analyse-
it set of macroinstructions (Analyse-it Software Ltd, Leeds,
UK). A Kolmogorov Smirnov test was used to determine the
data distribution. Results obtained before and after racing
were compared to each other using a Wilcoxon paired t-
test. A Mann-Withney U test was employed to compare to
each other the results from group NC and E either pre-
race or post-race. Diﬀerences were considered signiﬁcant at
P<. 05.
3. Results
3.1. Hematology. None of the horses enrolled in the study
had signs of hepatic or renal failure (data not shown) or
hematological changes potentially inﬂuencing the coagula-
tion process (Table 1).
Prerace RBCs were signiﬁcantly higher in controls than
in horses with EIPH. By contrast, no signiﬁcant diﬀerences
were found between the hematocrit (Hct) of controls and of
horses with EIPH. None of the horses was anemic or had
RBC or Hct values higher than the reference range of the
laboratory.
After the race, a signiﬁcant increase of RBCs and Hct,
compared with pre-race values, both in controls and in
horses with EIPH was detected. Also after the race, however,
none of the horses had RBC or Hct values higher than
the reference range, indicating that exercise induced only
a “relative hemoconcentration” (i.e., an increase of Hct or
RBC numbers compared with pre-race values) and not a
“true hemoconcentration” (i.e., an increase of Hct or RBC
numbers up to values higher than the upper reference limit).
No diﬀerences between RBC or Hct values recorded in
controlsandinhorseswithEIPHweredetectedaftertherace.
Nosigniﬁcantdiﬀerencesbetweenthegroupswerefound
in pre-race WBC or platelet counts. In both the groups,
post-race samples were not signiﬁcantly diﬀerent compared
with the pre-race ones. After the race, the platelet number
of horses with EIPH was signiﬁcantly higher than that of
controls.
3.2. Thromboelastometric Results. Thromboelastometric
results are summarized in Tables 2 (pre-race) and 3
(post-race).4 Veterinary Medicine International
Table 2: Mean values ± standard deviation (median values) recorded before the race.
CT (sec) CFT (sec) MCF (mm) α (◦) Vmax (mm/min) AUC (mm2)
EXT
NC 56.7 ±14.6 140. ±19.35 4 .4 ±5.06 8 .0 ±5.41 2 .3 ±2.5 5420.1 ±498.6
(59.0) (140.0) (54.0) (70.0) (11.0) (5358.0)
E 49.9 ±4.6 122.7 ±24.15 7 .8 ±4.57 1 .7 ±5.01 4 .7 ±4.1 5754.0 ±411.3
(48.4) (127.8) (57.6) (70.5) (14.1) (5739.3)
INT
NC 277.0 ±37.5 124.1 ±22.54 7 .0 ±5.86 6 .1 ±3.71 2 .1 ±6.0 4739.0 ±587.8
(287.0) (124.0) (45.0) (66.0) (10.0) (4595.0)
E 291.1 ±33.5 100.6 ±12.55 0 .3 ±4.46 9 .9 ±1.71 4 .0 ±3.9 4965.4 ±418.2
(294.3) (102.2) (49.8) (69.8) (12.8) (4871.2)
FIB†
NC 51.0 ±4.5 Nd 15.3 ±3.37 0 .7 ±6.91 4 .6 ±2.7 1504.0 ±329.2
(51.0) (15.0) (72.0) (14.0) (1485.0)
E 47.4 ±3.2 Nd 16.9 ±3.47 5 .2 ±2.71 7 .0 ±3.6 1673.6 ±368.5
(47.5) (16.5) (74.0) (16.0) (1623.0)
LYS†
NC 50.5 ±3.4 162.0 ±22.54 8 .7 ±3.16 5 .8 ±7.01 1 .2 ±2.6 4825.8 ±297.6
(50.5) (165.5) (48.5) (67.5) (12.0) (4783.5)
E 52.6 ±5.7 142.9 ±31.65 3 .8 ±4.26 7 .3 ±7.71 4 .0 ±3.8 5345.4 ±483.0
(53.5) (140.0) (53.5) (66.0) (13.5) (5305.0)
NC: negative controls; E: EIPH; EXT: extrinsic pathway; INT: intrinsic pathway; FIB: ﬁbrinogen activity; LYS: ﬁbrinolysis; nd: not determinable; inb o l dP<
.05 versus the pre-race NC value; † Fibrinogen and ﬁbrinolytic activities were determined in only 11 samples.
Table 3: Mean values ± standard deviation (median values) recorded after the race.
CT (sec) CFT (sec) MCF (mm) α (◦) Vmax (mm/min) AUC (mm2)
EXT
NC 58.4 ±10.4 150.4 ±29.65 1 .4 ± 5.46 3 .8 ±6.11 1 .0 ±2.3 5126.6 ±511.0
(57.0) (148.0)
∗ (53.0)
∗ (66.0)
∗ (11.0) (5252.0)
∗
E 51.3 ±7.9 137.8 ±28.55 6 .8 ± 5.46 6 .8 ±6.51 1 .3 ±2.1 5324.1 ±367.5
(51.7) (136.1)
∗ (56.1) (67.2) (11.9) (5343.0)
∗
INT
NC 257. ±45.66 131.0 ±28.34 5 .0 ± 5.16 6 .2 ±4.01 1 .0 ±2.2 4527.8 ±501.3
(234.0) (135.0) (43.0) (66.0) (10.0) (4318.0)
E 262.6 ±42.1 101.9 ±15.44 9 .8 ± 5.47 2 .0 ±3.51 4 .0 ±2.1 5002.2 ±415.0
(247.9) (100.6)
∗ (49.9)
∗ (71.0) (14.1) (4951.2)
∗
FIB†
NC 52.0 ±6.2 Nd 14.0 ± 3.66 8 .0 ±4.21 1 .4 ±2.9 1341.3 ±348.2
(54.0) (14.0)
∗ (68.0) (12.0)
∗ (1328.0)
∗
E 48.2 ±6.2 Nd 14.1 ± 3.97 0 .9 ±8.81 3 .9 ±5.1 1376.0 ±414.7
(48.0) (15.0)
∗ (75.0) (14.0)
∗ (1398.0)
∗
LYS†
NC 53.5 ±5.9 180.5 ±23.74 6 .0 ± 3.06 1 .0 ±7.11 0 .0 ±2.4 4575.2 ±269.7
(53.5) (183.0) (45.0) (60.5) (10.5) (4511.5)
E 47.3 ±5.3 144.7 ±31.35 2 .2 ± 4.86 6 .5 ±6.31 2 .2 ±2.5 5278.5 ±475.5
(47.5) (144.0) (52.0)
∗ (67.0) (12.0)
∗ (5186.5)
NC: negative controls; E: EIPH; EXT: extrinsic pathway; INT: intrinsic pathway; FIB: ﬁbrinogen activity; LYS: ﬁbrinolysis; nd: not determinable; inb o l d :
P<. 05 versus the post-race NC value; ∗P<. 05 versus the corresponding pre-race value of the same group; †Fibrinogen and ﬁbrinolytic activities were
determined in only 11 samples.
Compared with controls, in EIPH-aﬀected horses the
activation of clotting was more rapid than in controls
(shorter CT and CFT), as well as the whole coagulation
process (higher Vmax and AUC), and the clot was stronger
(higher MCF and α angle) both before and after racing.
This trend was evident in all the test but it was often
non statistically signiﬁcant, likely due to a high individual
variability. Signiﬁcant diﬀerences were recorded for the
intrinsic pathway (CFT, α angle and Vmax, in both pre- and
post-race samples) for ﬁbrinolysis (MCF and AUC in both
pre- and post-race samples) and for the extrinsic pathway
(CT in the post-race sample).
As a general trend, in both controls and EIPH-aﬀected
horses after racing the coagulability decreased (longer CT
and CFT and reduced MCF). Speciﬁcally, the diﬀerences
between pre- and post-race results were rarely signiﬁcant
only for the extrinsic pathway (increased CFT and decreased
AUC for both groups, lower α angle and MCF for controls)
and the intrinsic pathway (longer CFT and reduced MCF
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(reduced MCF, Vmax, and AUC for both groups) and for
ﬁbrinolysis (reduced MCF and Vmax in horses with EIPH).
4. Discussion
Bothhematologicalandtromboelastometricresultsrecorded
in controls either before or after the race were similar
to those obtained in a previous study [8]. Basically, these
results conﬁrm that exercise induces a moderate relative
hemoconcentration and reduces the coagulability in healthy
animals.
Compared with controls, EIPH-aﬀected horses showed
a trend to a hypercoagulable state (shorter times of clot
activation and higher clot ﬁrmness for most of the consid-
ered tests) before the race, when, however, many diﬀerences
were not statistically signiﬁcant, likely due to the individual
variability. In a previous study it has been demonstrated that
hypercoagulability can depend on a decreased RBC mass [8]
but it is unlikely that this occurred in EIPH horses before the
race since, in spite of a lower number of RBCs, the erythroid
mass was not decreased, as demonstrated by the lack of
signiﬁcant diﬀerences of Hct. Similarly, the hypercoagulabil-
ity recorded in horses with EIPH before the race does not
depend on a diﬀerent platelet number, since no signiﬁcant
diﬀerences regarding platelet counts of the two groups were
recorded. Theoretically, the increased coagulability recorded
after the race could depend on hyperﬁbrinogenemia. The
concentration of ﬁbrinogen has not been measured using
standard methods but in previous studies it has been
demonstrated that the concentration of ﬁbrinogen correlates
well with the thromboelastometric evaluation of ﬁbrinogen
[5]. It is thus unlikely that horses included in this study were
hyperﬁbrinogenemic either before or after the race since in
both samplings the activity of ﬁbrinogen was comparable
with that previously recorded in healthy horses [8].
After the race coagulability decreased (thromboelas-
tograms characterised by longer CT and CFT and less
eﬀective clot ﬁrmness) also in horses aﬀected by EIPH,
as in controls, probably due to the hemoconcentration
recorded in both groups, since, as previously mentioned,
an inverse correlation between the erythroid mass and most
TEM parameters has been demonstrated [8]. The immediate
consequence of the parallel behaviour of TEM parameters
in the two groups is that also after the race EIPH horses
have a “hypercoagulable state” compared with controls,
and, also in this case, this phenomenon cannot depend on
diﬀerences of Hct or RBC counts, since these parameters
were not signiﬁcantly diﬀe r e n ti nE I P Hg r o u p sc o m p a r e d
with controls. Conversely, the hypercoagulability could be
associatedwiththehighplateletcountrecordedaftertherace
in EIPH horses.
These results suggest that in EIPH-aﬀected horses
hemostasis is activated in spite of the lack of diﬀerences
in prothrombin time and in activated thromboplastin time
demonstrated by others [4].
The results of the present study do not allow to
understand the cause and/or the mechanism responsible
for the trend to hypercoagulability recorded in horses with
EIPH. All the hemostatic pathways, including ﬁbrinolysis,
showed the same trend, although with diﬀerent intensity.
It is thus unlikely that the increased coagulability depends
on a primary activation of a speciﬁc step of the hemostasis.
Rather, previous studies demonstrated that an increased
coagulability can be detected by thromboelastometry when
coagulation is activated by spontaneous or surgical bleeding
[5]. It is possible that TEM results in EIPH horses depend
on recent hemorrhagic episodes occurred before the pre-race
sampling or on recurrent hemorrhage which could “chroni-
cally” activate coagulation. If this interpretation is correct,
the mechanism responsible for the hemorrhage remains to
be elucidated. All the hypotheses raised in the past about the
pathogenesis of EIPH [1–3] can be possibly involved in the
damage of vessel walls. Further studies should be designed in
the future to assess whether the hypercoagulability detected
before the race is only a consequence of hemorrhage or if it
could work as a predisposing factor for EIPH.
5. Conclusions
The results of this study provide useful additional informa-
tion to the understanding of the pathogenesis of EIPH in
horses: speciﬁcally, TEM analysis conﬁrmed that EIPH is
not associated with decreased blood coagulability. On the
contrary, horses aﬀected by EIPH tend to be hypercoagulable
before the race, possibly due to pre-existing hemorrhage.
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